0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

More on Thrombolytic Therapy for Acute Stroke

Michael P. Sluss, MD
JAMA. 1998;279(16):1262. doi:10-1001/pubs.JAMA-ISSN-0098-7484-279-16-jac80007.
Text Size: A A A
Published online

Extract

To the Editor.—In his Letter to the Editor, Dr Alexander1 asserts that recombinant tissue-type plasminogen activator (rt-PA) given for acute ischemic stroke "may not increase the risk of hemorrhagic transformation." Alexander refers to the study by Larrue et al,2 which defined parenchymal hemorrhage to be the clinically significant type of hemorrhagic transformation, and showed parenchymal hemorrhage to occur 3 times more frequently in patients treated with rt-PA compared with those treated with placebo. This risk of hemorrhage can be compared with the results of the National Institutes of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study,3 which showed that patients treated with rt-PA were 11 times more likely to develop symptomatic nonfatal hemorrhage and were 9 times more likely to die of intracranial hemorrhage than were patients treated with placebo. These data emphasize the importance for a physician never to underestimate the risks of intravenous rt-PA administered during acute stroke.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();